Efficacy of first-line bevacizumab (Bev) combined with weekly paclitaxel (wPac) for HER2-negative metastatic breast cancer (MBC): Results of a Japanese phase II study (n=120).
Y. Ito
No relevant relationships to disclose
K. Aogi
No relevant relationships to disclose
N. Masuda
No relevant relationships to disclose
S. Ohno
No relevant relationships to disclose
T. Oda
No relevant relationships to disclose
H. Iwata
Honoraria - Chugai Pharma
M. Kashiwaba
No relevant relationships to disclose
Y. Fujiwara
Honoraria - Abbott Laboratories; Chugai Pharma; Lilly; Sanofi ; Taiho Pharmaceutical
Research Funding - Chugai Pharma; Daiichi Sankyo; Eisai; GlaxoSmithKline; Nippon Kayaku; Pfizer; Taiho Pharmaceutical
S. Kamigaki
No relevant relationships to disclose
T. Ueno
No relevant relationships to disclose
S. Takashima
No relevant relationships to disclose